Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631443 | 0.98 | ALDH1A1 (0.44) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17560397 | 0.81 | CA2 (0.42) | ALDH1A1HSD11B1HPGD | |
| SCHEMBL18343858 | 0.78 | ALDH1A1 (0.38) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27094467 | 0.77 | ALDH1A1 (0.41) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3631440 | 0.77 | ALDH1A1 (0.41) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18343883 | 0.74 | ALDH1A1 (0.34) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26185312 | 0.74 | ALDH1A1 (0.40) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20599718 | 0.73 | ALDH1A1 (0.36) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1817154 | 0.72 | SMN1; SMN2 (0.40) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20703526 | 0.72 | ALDH1A1 (0.37) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023140369-A1 | PHOSPHORIC ACID DERIVATIVES | Prism BioLab Co., Ltd. (JP) | 2023-07-27 | — | — | WO | disclosed |
| WO-2017186148-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE BCR-ABL INHIBITORS | ASTAR BIOTECH LLC (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20080039438-A1 | 1B-Methylcarbapenem Derivative and Process for the Preparation Thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-02-14 | — | — | US | disclosed |
| EP-1765822-A1 | 1ß-METHYLCARBAPENEM DERIVATIVE AND PROCESS FOR THE PREPARATION THEREOF | Korea Institute of Science and Technology (KR) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005121144-A1 | 1ß-METHYLCARBAPENEM DERIVATIVE AND PROCESS FOR THE PREPARATION THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039438-A1 | 1B-Methylcarbapenem Derivative and Process for the Preparation Thereof | CYP4B1, MEP1B, CYP1B1 | ALDH1A1 1473/4885POLB 1027/4885MEN1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.